Given that TRAF6 deficiency in Tregs effectively prevented the establishment of tumor‐enforced immune tolerance, pharmacological targeting of TRAF6 may be a potent means to improve anti‐tumor immunity. The gene discussed is TRAF6; the disease is neoplasm.